Compare IMNM & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | TWST |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2020 | 2018 |
| Metric | IMNM | TWST |
|---|---|---|
| Price | $19.42 | $31.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $26.89 | ★ $46.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,679,000.00 | ★ $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $5.15 | $23.30 |
| 52 Week High | $20.46 | $55.33 |
| Indicator | IMNM | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 54.50 |
| Support Level | $16.81 | $28.90 |
| Resistance Level | $20.46 | $33.24 |
| Average True Range (ATR) | 1.20 | 1.78 |
| MACD | 0.03 | 0.39 |
| Stochastic Oscillator | 72.74 | 79.91 |
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.